SRI INTERNATIONAL

MENLO PARK, CA

OncologyantibodyPhase II

Compare Sign in to watch

What changed

Study registered, no phase assigned: Multi-omics Study of Early-stage Lung Cancer With Distinct Phenotypes

1w agoTrial registeredJul 7, 2026Source filing (opens the source filing in a new tab)

Momentum

99no change

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

946 pre-ticker oncology companies at Phase II

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Trial
PHASE2 registered
May 1, 2026
Head and Neck Squamous Cell Carcinoma · NOT_YET_RECRUITING · sponsor: Sun Yat-sen University · Becotatug Vedotin Combined With Pucotenlimab as Neoadjuvant Therapy for Resectable Recurrent Head and Neck Squamous Cell Carcinoma After Progression on Immunotherapy: A Prospective Phase II Study
ClinicalTrials.gov · NCT07589049 (opens the source filing in a new tab)
Trial
Study registered
Dec 1, 2025
Lung Cancer, PET-CT · RECRUITING · sponsor: Shanghai Pulmonary Hospital, Shanghai, China · Synthetic PET From CT Improves Precision Diagnosis and Treatment of Lung Cancer: a Prospective, Observational, Multicenter Study
ClinicalTrials.gov · NCT07243873 (opens the source filing in a new tab)
Grant
R03 · $321k · non-dilutive
Jun 10, 2025
MAYO CLINIC ROCHESTER · PI CHEN, WENAN · OD · award ends Nov 30, 2026 · Rare variant analysis integrating large public DNA sequencing controls and gene expression data for discovering novel predisposition genes of orofacial clefts
NIH RePORTER · NIH RePORTER 11125052 (opens the source filing in a new tab)
Grant
K08 · $174k · non-dilutive
May 1, 2025
UNIVERSITY OF PENNSYLVANIA · PI WANG, LEO LE · NIAMS · award ends Jul 31, 2025 · Hydrogel Therapies for Alopecia Areata
NIH RePORTER · NIH RePORTER 11136601 (opens the source filing in a new tab)
Grant
R03 · $314k · non-dilutive
May 1, 2025
UNIVERSITY OF CALIFORNIA-IRVINE · PI SUBRAMANIAN, VEEDAMALI S · NIA · award ends Apr 30, 2027 · Molecular mechanisms underlying reduced vitamin C transport process in Alzheimer's disease and its impact on neuroinflammation
NIH RePORTER · NIH RePORTER 11125200 (opens the source filing in a new tab)
Grant
F30 · $55k · non-dilutive
Apr 18, 2025
UNIVERSITY OF ILLINOIS AT CHICAGO · PI WANG, LUYU · NIEHS · award ends Mar 31, 2029 · Lipid-Based Interventions to Mitigate the Impact of Arsenic on Microglial Function and Neurobehavior
NIH RePORTER · NIH RePORTER 11162649 (opens the source filing in a new tab)
Grant
R01 · $589k · non-dilutive
Apr 18, 2025
UNIVERSITY OF MISSOURI-COLUMBIA · PI LIU, XIAOHUA · NIDCR · award ends Mar 31, 2030 · Sharpey's fibers and PDL regeneration
NIH RePORTER · NIH RePORTER 11159166 (opens the source filing in a new tab)
Grant
K99 · $163k · non-dilutive
Apr 1, 2025
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHEN, WILLIAM C · NCI · award ends Mar 31, 2027 · Chromosomal instability and radiation sensitivity in meningioma
NIH RePORTER · NIH RePORTER 11036124 (opens the source filing in a new tab)
Grant
K99 · $176k · non-dilutive
Apr 1, 2025
MASSACHUSETTS GENERAL HOSPITAL · PI CHEN, CHANG-YU ALEX · NCI · award ends Mar 31, 2027 · The effect of aging on cDC1 function and CD8 T cell immunity in tumors
NIH RePORTER · NIH RePORTER 11031755 (opens the source filing in a new tab)
Grant
R01 · $606k · non-dilutive
Mar 1, 2025
UNIV OF NORTH CAROLINA CHAPEL HILL · PI WANG, LI · NIBIB · award ends Dec 31, 2028 · Continued Development of Infant Neuroimaging Analysis Tools
NIH RePORTER · NIH RePORTER 11140142 (opens the source filing in a new tab)
Grant
R35 · $423k · non-dilutive
Jan 9, 2025
MICHIGAN STATE UNIVERSITY · PI CHEN, CHEN · NIGMS · award ends Dec 31, 2029 · Genetic and biochemical dissection of mammalian pachytene piRNA biogenesis.
NIH RePORTER · NIH RePORTER 11010981 (opens the source filing in a new tab)
Grant
R01 · $735k · non-dilutive
Sep 15, 2024
UNIVERSITY OF SOUTH FLORIDA · PI MOHAPATRA, SUBHRA · NIA · award ends May 31, 2029 · Molecular Targets Modulating Neuro COVID Sequelae Linked to Tauopathy
NIH RePORTER · NIH RePORTER 11192311 (opens the source filing in a new tab)
Trial
Study registered
Aug 29, 2024
Lung Cancer Associated With Cystic Airspaces, Multiple Primary Lung Cancers, Non-Small Cell Lung Cancer · RECRUITING · sponsor: Central South University · Multi-omics Study of Early-stage Lung Cancer With Distinct Phenotypes
ClinicalTrials.gov · NCT06699979 (opens the source filing in a new tab)
Grant
R01 · $587k · non-dilutive
Aug 15, 2024
UNIVERSITY OF MARYLAND BALTIMORE · PI CHEN, CHIXIANG · NIA · award ends Apr 30, 2029 · Developing a Novel Analytical Toolbox to Tackle Multifaceted Statistical Challenges in Analyzing Post-Fracture Recovery Trajectories in Older Adults with ADRD
NIH RePORTER · NIH RePORTER 11167725 (opens the source filing in a new tab)
Grant
R21 · $203k · non-dilutive
Aug 12, 2024
UNIVERSITY OF PENNSYLVANIA · PI CHEN, CHI-DER · NIDCR · award ends Jul 31, 2027 · Repurposing Ferumoxytol Nanoparticles to Promote Orofacial Stem Cell Function for Autotherapies
NIH RePORTER · NIH RePORTER 11167761 (opens the source filing in a new tab)
Grant
R01 · $657k · non-dilutive
Jul 1, 2024
METHODIST HOSPITAL RESEARCH INSTITUTE · PI ZHOU, LAN · NCI · award ends Jun 30, 2026 · Mechanisms of JAG1-mediated immune suppression in the pancreatic cancer microenvironment
NIH RePORTER · NIH RePORTER 11127786 (opens the source filing in a new tab)
Grant
R01 · $372k · non-dilutive
Jun 5, 2024
UNIVERSITY OF PENNSYLVANIA · PI CHEN, CHI-DER · NCI · award ends May 31, 2029 · Stromal Effects in Head and Neck Squamous Cell Carcinoma
NIH RePORTER · NIH RePORTER 11106040 (opens the source filing in a new tab)
Grant
R21 · $209k · non-dilutive
Jun 1, 2024
YALE UNIVERSITY · PI LIU, XIAOFENG · NIBIB · award ends Mar 31, 2027 · Deep Learning for Individualized Treatment Effect Inference with Multimodal Depiction
NIH RePORTER · NIH RePORTER 11094158 (opens the source filing in a new tab)
Grant
R21 · $346k · non-dilutive
Jun 1, 2024
SRI INTERNATIONAL · PI LIU, XIAOHE · NCI · award ends Nov 30, 2026 · Pilot in vivo trial with T-cell-based delivery of immunostimulatory proteins
NIH RePORTER · NIH RePORTER 11064775 (opens the source filing in a new tab)
Grant
R21 · $205k · non-dilutive
Apr 10, 2024
UT SOUTHWESTERN MEDICAL CENTER · PI LIU, XIN · NINDS · award ends Mar 31, 2027 · Understanding Molecular Crosstalk Between EZHIP and PRC2 in PFA Ependymoma
NIH RePORTER · NIH RePORTER 11067759 (opens the source filing in a new tab)
Grant
R01 · $652k · non-dilutive
Apr 1, 2024
UNIVERSITY OF SOUTH FLORIDA · PI LIU, RUISHENG · NIDDK · award ends Mar 31, 2029 · Protection of donor kidney and transplanted graft function by modulating Na/K ATPase activity
NIH RePORTER · NIH RePORTER 11063102 (opens the source filing in a new tab)
Grant
R01 · $630k · non-dilutive
Sep 15, 2023
UNIVERSITY OF ARIZONA · PI CHEN, CHEN X · NICHD · award ends May 31, 2028 · Vaginal Microbiome, Inflammatory Mediators, Metabolome, and Dysmenorrhea Symptom-based Phenotypes
NIH RePORTER · NIH RePORTER 11129803 (opens the source filing in a new tab)
Grant
P50 · $251k · non-dilutive
Aug 8, 2023
MASSACHUSETTS GENERAL HOSPITAL · PI LIU, RICHARD T · NIMH · award ends May 31, 2028 · Improving Suicide Risk Prediction in Racial, Ethnic, and Linguistic Minority Youth
NIH RePORTER · NIH RePORTER 11098699 (opens the source filing in a new tab)
Grant
R01 · $631k · non-dilutive
Jul 1, 2023
UNIVERSITY OF KENTUCKY · PI LIU, XIAOQI · NCI · award ends Jun 30, 2028 · Targeting the Plk1/Pdcd4/mTORC2 Signaling to Treat Castration-Resistant Prostate Cancer
NIH RePORTER · NIH RePORTER 11131062 (opens the source filing in a new tab)
Grant
R01 · $541k · non-dilutive
Jun 26, 2023
CASE WESTERN RESERVE UNIVERSITY · PI KARATHANASIS, EFSTATHIOS · NCI · award ends May 31, 2028 · Dual action immunostimulatory nanoparticles for treatment of aggressive cancers
NIH RePORTER · NIH RePORTER 11092920 (opens the source filing in a new tab)
Grant
R01 · $1.1M · non-dilutive
Jun 9, 2023
UNIVERSITY OF MARYLAND BALTIMORE · PI BARRY, EILEEN M. · NIAID · award ends May 31, 2028 · Advanced Development of a Combined Shigella-ETEC Vaccine
NIH RePORTER · NIH RePORTER 11085911 (opens the source filing in a new tab)
Grant
R01 · $538k · non-dilutive
May 1, 2023
OHIO STATE UNIVERSITY · PI LIU, XUEFENG · NCI · award ends Apr 30, 2028 · Developing Functional Human Cell Models to Study Initiation and Progression of Prostate Cancer between AA and EA men
NIH RePORTER · NIH RePORTER 11079446 (opens the source filing in a new tab)
Grant
R01 · $567k · non-dilutive
Apr 1, 2023
UNIVERSITY OF SOUTH FLORIDA · PI LIU, RUISHENG · NIDDK · award ends Mar 31, 2028 · Treatment of lupus nephritis with nanoparticles that selectively target kidney glomeruli
NIH RePORTER · NIH RePORTER 11115578 (opens the source filing in a new tab)
Grant
R01 · $660k · non-dilutive
Aug 29, 2022
UNIVERSITY OF SOUTH FLORIDA · PI LIU, RUISHENG · NIDDK · award ends Apr 30, 2027 · Tubuloglomerular feedback response in AKI to CKD transition
NIH RePORTER · NIH RePORTER 11113929 (opens the source filing in a new tab)
Grant
R00 · $249k · non-dilutive
Aug 5, 2022
UNIVERSITY OF SOUTHERN CALIFORNIA · PI WANG, LU · NINDS · award ends May 31, 2028 · A Phenotypical Brain Organoids for Neurodevelopmental Disorders
NIH RePORTER · NIH RePORTER 10973761 (opens the source filing in a new tab)
Grant
R01 · $573k · non-dilutive
Jun 10, 2022
OHIO STATE UNIVERSITY · PI LIU, XIAOGUANG MARGARET · NCI · award ends May 31, 2027 · Combine mitochondrial gene therapy and synthetic lethal chemotherapy to treat triple-negative breast cancer
NIH RePORTER · NIH RePORTER 11094833 (opens the source filing in a new tab)
Grant
P01 · $360k · non-dilutive
Feb 1, 2022
SCRIPPS RESEARCH INSTITUTE, THE · PI CHEN, CHRISTOPHER YEH · NIAID · award ends Jan 31, 2027 · Core-002 - Non-Human Primate Core
NIH RePORTER · NIH RePORTER 11015062 (opens the source filing in a new tab)
Grant
R01 · $654k · non-dilutive
Jul 8, 2021
THOMAS JEFFERSON UNIVERSITY · PI YANG, HUSHAN · NCI · award ends Jun 30, 2027 · Genomic profiling of single circulating tumor cells in the precision medicine of metastatic prostate cancer
NIH RePORTER · NIH RePORTER 11099957 (opens the source filing in a new tab)
Grant
P20 · $681k · non-dilutive
Feb 15, 2021
UNIVERSITY OF DELAWARE · PI WANG, LIYUN · NIGMS · award ends Jan 31, 2027 · Delaware Center for Musculoskeletal Research – Multiscale Assessments Research Core
NIH RePORTER · NIH RePORTER 11026350 (opens the source filing in a new tab)
Grant
R00 · $244k · non-dilutive
Jun 1, 2020
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI WANG, LU · NIA · award ends May 31, 2027 · Mechanisms of enhancer regulation in aging and age-related diseases
NIH RePORTER · NIH RePORTER 11086846 (opens the source filing in a new tab)
Grant
R01 · $85k · non-dilutive
Jan 1, 2020
UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LIU, RUNHUA RUNA · NCI · award ends Feb 28, 2026 · Synergistic Targeted Therapy of Antibody-Drug Conjugates for Triple-Negative Breast Cancer
NIH RePORTER · NIH RePORTER 11001831 (opens the source filing in a new tab)
Trial
NA registered
Sep 1, 2019
Stroke Associated Pneumonia, Non Severe Ischemic Stroke, Dysphagia · COMPLETED · sponsor: The First People's Hospital of Zunyi · Study on the Treatment of Post-stroke Dysphagia and Stroke-associated Pneumonia With Bronchoscopy
ClinicalTrials.gov · NCT07345078 (opens the source filing in a new tab)
Grant
R01 · $558k · non-dilutive
Jul 15, 2017
UNIVERSITY OF FLORIDA · PI ZHOU, LIANG · NIAID · award ends Jun 30, 2028 · Regulation of Gut Innate Lymphoid Cells by Ahr
NIH RePORTER · NIH RePORTER 11124724 (opens the source filing in a new tab)
Grant
R01 · $554k · non-dilutive
Apr 1, 2016
AUGUSTA UNIVERSITY · PI CHEN, WEIQIN · NHLBI · award ends May 31, 2028 · Novel Role of Bscl2 in Cardiac Substrate Metabolism and Function
NIH RePORTER · NIH RePORTER 11089385 (opens the source filing in a new tab)
Grant
U24 · $4.8M · non-dilutive
Apr 1, 2012
UNIVERSITY OF PENNSYLVANIA · PI WANG, LI-SAN · NIA · award ends Apr 30, 2027 · THE NIA GENETICS OF ALZHEIMER'S DISEASE DATA STORAGE SITE
NIH RePORTER · NIH RePORTER 11077287 (opens the source filing in a new tab)
Grant
R01 · $573k · non-dilutive
Jul 1, 2006
EMORY UNIVERSITY · PI LIU, ROBERT C · NIDCD · award ends Jun 30, 2029 · Functional approach to communication sound processing in mouse auditory cortex
NIH RePORTER · NIH RePORTER 11105986 (opens the source filing in a new tab)
Grant
R01 · $748k · non-dilutive
Sep 1, 2003
BOSTON CHILDREN'S HOSPITAL · PI CHEN, CHINFEI · NEI · award ends May 31, 2030 · Plasticity of the Retinogeniculate Synapse
NIH RePORTER · NIH RePORTER 11167998 (opens the source filing in a new tab)
Grant
P30 · $213k · non-dilutive
Sep 1, 1997
UNIVERSITY OF CHICAGO · PI CHEN, CHIN-TU · NCI · award ends Mar 31, 2029 · Integrated Small Animal Imaging Research Resource
NIH RePORTER · NIH RePORTER 11061436 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 100%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the grant record at 0.75principal investigator LIU, XIAOHUA is named on this company's filings
Shared principal investigator or founder links the grant record at 0.75principal investigator LIU, XIAOFENG is named on this company's filings
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75principal investigator CHEN, CHANG-YU ALEX is named on this company's filings
Shared principal investigator or founder links the grant record at 0.75principal investigator CHEN, CHEN is named on this company's filings
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75principal investigator WANG, LEO LE is named on this company's filings
Shared principal investigator or founder links the grant record at 0.75principal investigator SUBRAMANIAN, VEEDAMALI S is named on this company's filings
Shared principal investigator or founder links the grant record at 0.75principal investigator WANG, LUYU is named on this company's filings
Shared principal investigator or founder links the grant record at 0.75principal investigator CHEN, WILLIAM C is named on this company's filings
Shared principal investigator or founder links the grant record at 0.75principal investigator WANG, LI is named on this company's filings
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
new_entity links the grant record at 0.27same therapeutic area

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Investigators

The principal investigators named on the grants below. Each links to their federal grant record and every other company traced to their work.

Event stream

Every scored event, newest first. This is what momentum is computed from.

Study registered, no phase assigned: Multi-omics Study of Early-stage Lung Cancer With Distinct Phenotypes
1w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Multi-omics Study of Early-stage Lung Cancer With Distinct Phenotypes
1w agoTrial recruitingSource (opens the source filing in a new tab)
Phase II trial registered: Becotatug Vedotin Combined With Pucotenlimab as Neoadjuvant Therapy for Resectable Recurrent Head and Neck Squamous Cell Carcinoma After Progression on Immunotherapy: A Prospective Phase II Study
2mo agoTrial registeredSource (opens the source filing in a new tab)
Study registered, no phase assigned: Study on the Treatment of Post-stroke Dysphagia and Stroke-associated Pneumonia With Bronchoscopy
6mo agoTrial registeredSource (opens the source filing in a new tab)
Trial completed: Study on the Treatment of Post-stroke Dysphagia and Stroke-associated Pneumonia With Bronchoscopy
6mo agoTrial completedSource (opens the source filing in a new tab)
Study registered, no phase assigned: Synthetic PET From CT Improves Precision Diagnosis and Treatment of Lung Cancer: a Prospective, Observational, Multicenter Study
7mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Synthetic PET From CT Improves Precision Diagnosis and Treatment of Lung Cancer: a Prospective, Observational, Multicenter Study
7mo agoTrial recruitingSource (opens the source filing in a new tab)
NIH R01 · $0.7M · Plasticity of the Retinogeniculate Synapse
Jun 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.6M · Regulation of Gut Innate Lymphoid Cells by Ahr
Jun 2025Grant renewalSource (opens the source filing in a new tab)
NIH P50 · $0.3M · Improving Suicide Risk Prediction in Racial, Ethnic, and Linguistic Minority Youth
Jun 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.6M · Novel Role of Bscl2 in Cardiac Substrate Metabolism and Function
Jun 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.6M · Functional approach to communication sound processing in mouse auditory cortex
Jun 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.7M · Genomic profiling of single circulating tumor cells in the precision medicine of metastatic prostate cancer
Jun 2025Grant renewalSource (opens the source filing in a new tab)
NIH R03 · $0.3M · Rare variant analysis integrating large public DNA sequencing controls and gene expression data for discovering novel predisposition genes of orofacial clefts
Jun 2025New grantSource (opens the source filing in a new tab)
NIH R01 · $0.7M · Mechanisms of JAG1-mediated immune suppression in the pancreatic cancer microenvironment
Jun 2025Grant renewalSource (opens the source filing in a new tab)
NIH R21 · $0.2M · Repurposing Ferumoxytol Nanoparticles to Promote Orofacial Stem Cell Function for Autotherapies
Jun 2025Grant renewalSource (opens the source filing in a new tab)
NIH R00 · $0.2M · A Phenotypical Brain Organoids for Neurodevelopmental Disorders
May 2025Grant renewalSource (opens the source filing in a new tab)
NIH P20 · $0.7M · Delaware Center for Musculoskeletal Research – Multiscale Assessments Research Core
May 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $1.1M · Advanced Development of a Combined Shigella-ETEC Vaccine
May 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.6M · Vaginal Microbiome, Inflammatory Mediators, Metabolome, and Dysmenorrhea Symptom-based Phenotypes
May 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.7M · Tubuloglomerular feedback response in AKI to CKD transition
May 2025Grant renewalSource (opens the source filing in a new tab)
NIH P01 · $0.4M · Core-002 - Non-Human Primate Core
May 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.6M · Treatment of lupus nephritis with nanoparticles that selectively target kidney glomeruli
May 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.7M · Protection of donor kidney and transplanted graft function by modulating Na/K ATPase activity
May 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.4M · Stromal Effects in Head and Neck Squamous Cell Carcinoma
May 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.6M · Targeting the Plk1/Pdcd4/mTORC2 Signaling to Treat Castration-Resistant Prostate Cancer
May 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.5M · Dual action immunostimulatory nanoparticles for treatment of aggressive cancers
May 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.7M · Molecular Targets Modulating Neuro COVID Sequelae Linked to Tauopathy
May 2025Grant renewalSource (opens the source filing in a new tab)
NIH R00 · $0.2M · Mechanisms of enhancer regulation in aging and age-related diseases
May 2025Grant renewalSource (opens the source filing in a new tab)
NIH U24 · $4.8M · THE NIA GENETICS OF ALZHEIMER'S DISEASE DATA STORAGE SITE
May 2025Grant renewalSource (opens the source filing in a new tab)
NIH P30 · $0.2M · Integrated Small Animal Imaging Research Resource
Apr 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.6M · Developing a Novel Analytical Toolbox to Tackle Multifaceted Statistical Challenges in Analyzing Post-Fracture Recovery Trajectories in Older Adults with ADRD
Apr 2025Grant renewalSource (opens the source filing in a new tab)
NIH R21 · $0.2M · Understanding Molecular Crosstalk Between EZHIP and PRC2 in PFA Ependymoma
Apr 2025Grant renewalSource (opens the source filing in a new tab)
NIH K08 · $0.2M · Hydrogel Therapies for Alopecia Areata
Apr 2025New grantSource (opens the source filing in a new tab)
NIH R03 · $0.3M · Molecular mechanisms underlying reduced vitamin C transport process in Alzheimer's disease and its impact on neuroinflammation
Apr 2025New grantSource (opens the source filing in a new tab)
NIH R01 · $0.1M · Synergistic Targeted Therapy of Antibody-Drug Conjugates for Triple-Negative Breast Cancer
Apr 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.6M · Combine mitochondrial gene therapy and synthetic lethal chemotherapy to treat triple-negative breast cancer
Apr 2025Grant renewalSource (opens the source filing in a new tab)
NIH R21 · $0.3M · Pilot in vivo trial with T-cell-based delivery of immunostimulatory proteins
Apr 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.6M · Sharpey's fibers and PDL regeneration
Apr 2025New grantSource (opens the source filing in a new tab)
NIH R01 · $0.5M · Developing Functional Human Cell Models to Study Initiation and Progression of Prostate Cancer between AA and EA men
Apr 2025Grant renewalSource (opens the source filing in a new tab)
NIH R21 · $0.2M · Deep Learning for Individualized Treatment Effect Inference with Multimodal Depiction
Mar 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.6M · Continued Development of Infant Neuroimaging Analysis Tools
Feb 2025New grantSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Peer position

Grant to raise

PHASE2 registered

Study registered

R03 · $321k · non-dilutive

K08 · $174k · non-dilutive

R03 · $314k · non-dilutive

F30 · $55k · non-dilutive

R01 · $589k · non-dilutive

K99 · $163k · non-dilutive

K99 · $176k · non-dilutive

R01 · $606k · non-dilutive

R35 · $423k · non-dilutive

R01 · $735k · non-dilutive

Study registered

R01 · $587k · non-dilutive

R21 · $203k · non-dilutive

R01 · $657k · non-dilutive

R01 · $372k · non-dilutive

R21 · $209k · non-dilutive

R21 · $346k · non-dilutive

R21 · $205k · non-dilutive

R01 · $652k · non-dilutive

R01 · $630k · non-dilutive

P50 · $251k · non-dilutive

R01 · $631k · non-dilutive

R01 · $541k · non-dilutive

R01 · $1.1M · non-dilutive

R01 · $538k · non-dilutive

R01 · $567k · non-dilutive

R01 · $660k · non-dilutive

R00 · $249k · non-dilutive

R01 · $573k · non-dilutive

P01 · $360k · non-dilutive

R01 · $654k · non-dilutive

P20 · $681k · non-dilutive

R00 · $244k · non-dilutive

R01 · $85k · non-dilutive

NA registered

R01 · $558k · non-dilutive

R01 · $554k · non-dilutive

U24 · $4.8M · non-dilutive

R01 · $573k · non-dilutive

R01 · $748k · non-dilutive

P30 · $213k · non-dilutive